Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 5, 2010, Pages 723-730

  Athyros, Vasilios G ^a   Mitsiou, Eydoxia K ^a   Tziomalos, Konstantinos ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Chronic kidney disease; Glomerular filtration rate; Statin; Type 2 diabetes mellitus

Indexed keywords

ATORVASTATIN; COLESEVELAM; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; DYSLIPIDEMIA; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RENAL PROTECTION; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT;

ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; SEVERITY OF ILLNESS INDEX;

EID: 77949428265     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903575654     Document Type: Review

References (60)

1. US Renal Data System. USRDS. Annual Data Report, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2003
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047
3. Stengel B, Billon S, Van Dijk PC, et al. Trends in the incidence of renal replacement therapy for end stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 2003;18:1824-1833
4. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-146
5. Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. Morb Mortal Wkly Rep 2007;56:161-165
6. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis 2007;49 (Suppl 1):A6-7, S1-S296
7. Preis SR, Pencina MJ, Hwang SJ, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the framingham heart study, 1950 to 2005. Circulation 2009;119:1728-1735
8. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on cardiovascular disease. Am J Kidney Dis 1998;32:853-906
9. Tonelli M, Keech A, Shepherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005;16:3748-3754
10. Shepherd J, Kastelein JP, Bittner VA, et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 2008;83:870-879
11. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-495
12. Athyros VG, Mitsiou EK, Tziomalos K, et al. Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective? Curr Vasc Pharmacol 2009. In Press
13. Wanner C, Krane V, März W, et al.; German Diabetes and Dialysis Study investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248
14. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol 2008;51:2375-2384
15. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990;13:153-169
16. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 1999;14:1462-1466
17. Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 1996;7:167-171
18. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861
19. Fazio S. More clinical lessons from the FIELD study. Cardiovasc Drugs Ther 2009;23:235-241
20. Hottelart C, el Esper N, Achard JM, et al. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie 1999;20:41-44
21. Chapman MJ. Pharmacology of fenofibrate. Am J Med 1987;83:21-25
22. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemia in chronic kidney disease. Am J Kidney Dis 2003;41(Suppl 3):S1-237
23. Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 2006;103:6682-6687
24. Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007;99:47C-55C
25. Yamada K, Fujimoto S, Tokura T, et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail 2005;27:361-365
26. Tziomalos K, Athyros VG, Mikhailidis DP. Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009;5:16-17
27. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Omega-3 fatty acids: how can they be used in secondary prevention? Curr Atheroscler Rep 2008;10:510-517
28. Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007;99:35C-43C
29. Landray M, Baigent C, Leaper C, et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 2006;47:385-395
30. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int 2003;63 (Suppl):S207-210
31. Colhoun HM, Betteridge DJ, Durrington PN, et al.; and CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009;54:810-819
32. Sever PS, Poulter NR, Dahlöf B, et al.; for the ASCOT Investigators. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes. Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care 2005;28:1151-1157
33. Knopp RH, D'Emden M, Smilde JH, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care 2006;29:1478-1485
34. Gazi IF, Mikhailidis DP. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Knopp. Diabetes Care 2006;29:2561
35. Rahman M, Baimbridge C, Davis BR, et al.; ALLHAT Collaborative Research Group. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis 2008;52:412-424
36. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs. usual care. JAMA 2002;288:2998-3007
37. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003;361:2005-2016
38. Athyros VG, Papageorgiou AA, Symeonidis AN, et al.; GREACE Study Collaborative Group. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003;54:679-690
39. Athyros VG, Papageorgiou AA, Elisaf M, et al. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003;19:615-617
40. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-127
41. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-734
42. Athyros VG, Kakafika AI, Papageorgiou AA, et al. Statin-Induced Increase in HDL-C and renal function in coronary heart disease patients. Open Cardiovasc Med J 2007;1:8-14
43. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305
44. Shepherd J, Kastelein JJ, Bittner V, et al.; for the TNT investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51:1448-1454
45. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-1295
46. Shepherd J, Kastelein JJ, Bittner V, et al.; for the TNT Steering Committee and investigators. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 2008;83:870-879
47. Stegmayr BG, Brännström M, Bucht S, et al.; for the Nediat Study Group. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scand J Urol Nephrol 2005;39:489-497
48. Fellström BC,Jardine AG,Schmieder RE, et al.; for the A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis (AURORA) study. rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-1407
49. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention. Curr Vasc Pharmacol 2009;7:264-266
50. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium-phosphorus product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998;31:607-617
51. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 2000;35:1226-1237
52. Efstratiadis G, Tziomalos K, Mikhailidis DP, et al. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 2008;6:93-107
53. Xinwei J, Xianghua F, Jing Z, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009;104:519-524
54. Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study. Am Heart J 2008;155:499.e1-8
55. Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008;101:279-285
56. Athyros VG, Hatzitolios A, Karagiannis A, et al.; INDEED Collaborative Group. Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. Curr Med Res Opin 2009;25:1931-1940
57. Jenkins AJ,Lyons TJ,Zheng D, et al.; DCCT/EDIC Research Group. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int 2003;64:817-828
58. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-462
59. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009;15(12):MS1-5
60. Paraskevas KI, Bessias N, Koupidis SA, et al. Incidence of end-stage renal disease in the elderly: a steadily rising global socioeconomic epidemic. Int Urol Nephrol 2009. [Epub ahead of print]